S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities

ChromaDex (CDXC) News Today

$3.94
+0.01 (+0.25%)
(As of 04/16/2024 ET)
SourceHeadline
marketbeat.com logoShort Interest in ChromaDex Co. (NASDAQ:CDXC) Grows By 12.8%
marketbeat.com - April 14 at 11:34 PM
MarketBeat logoChromaDex (NASDAQ:CDXC) Price Target Increased to $6.00 by Analysts at Roth Mkm
americanbankingnews.com - April 10 at 4:24 AM
marketbeat.com logoChromaDex (NASDAQ:CDXC) PT Raised to $6.00
marketbeat.com - April 9 at 10:13 AM
stocknews.com logo3 Chemical Stocks Poised for Gains
stocknews.com - March 27 at 5:01 PM
businesswire.com logoChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
businesswire.com - March 26 at 8:32 AM
marketbeat.com logoShort Interest in ChromaDex Co. (NASDAQ:CDXC) Declines By 9.0%
marketbeat.com - March 19 at 3:32 PM
marketbeat.com logoEquities Analysts Offer Predictions for ChromaDex Co.'s FY2025 Earnings (NASDAQ:CDXC)
marketbeat.com - March 14 at 7:36 AM
finance.yahoo.com logoChromaDex Full Year 2023 Earnings: EPS Beats Expectations
finance.yahoo.com - March 8 at 8:50 AM
marketbeat.com logoChromaDex Co. Forecasted to Earn Q1 2025 Earnings of $0.01 Per Share (NASDAQ:CDXC)
marketbeat.com - March 8 at 7:22 AM
uk.sports.yahoo.com logoPersona 3 Reload is getting the DLC it needs, but not the one it deserves
uk.sports.yahoo.com - March 8 at 1:24 AM
finance.yahoo.com logoChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 7 at 3:23 PM
finance.yahoo.com logoChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results with Positive Adjusted EBITDA
finance.yahoo.com - March 7 at 3:23 PM
markets.businessinsider.com logoWhat Wall Street expects from ChromaDex's earnings
markets.businessinsider.com - March 6 at 11:44 PM
investorplace.com logoCDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023
investorplace.com - March 6 at 11:01 PM
benzinga.com logoEarnings Preview For ChromaDex
benzinga.com - March 6 at 6:44 PM
finance.yahoo.com logoChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
finance.yahoo.com - March 6 at 6:44 PM
finance.yahoo.com logoInsiders own 26% of ChromaDex Corporation (NASDAQ:CDXC) shares but retail investors control 44% of the company
finance.yahoo.com - March 2 at 12:51 PM
finance.yahoo.com logoChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
finance.yahoo.com - February 21 at 12:29 PM
businesswire.com logoChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
businesswire.com - February 21 at 8:32 AM
entrepreneur.com logoTop 3 Accelerating Chemical Stocks to Consider
entrepreneur.com - February 6 at 10:27 AM
finance.yahoo.com logoChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
finance.yahoo.com - February 5 at 1:35 PM
finance.yahoo.com logoChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
finance.yahoo.com - January 26 at 6:46 PM
seekingalpha.com logoChromaDex: Growth At A Reasonable Price
seekingalpha.com - January 24 at 4:54 PM
finance.yahoo.com logoChromaDex Corporation's (NASDAQ:CDXC) Shift From Loss To Profit
finance.yahoo.com - January 19 at 9:29 AM
marketbeat.com logoChromaDex (NASDAQ:CDXC) Upgraded at StockNews.com
marketbeat.com - December 29 at 1:06 AM
businesswire.com logoChromaDex Supports the US Military with its Industry Leading NAD + Supplement, Tru Niagen
businesswire.com - December 20 at 3:28 PM
baystreet.ca logoChromaDex Flat on Assistance to Military
baystreet.ca - December 20 at 10:28 AM
finance.yahoo.com logoChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
finance.yahoo.com - December 20 at 10:28 AM
finance.yahoo.com logoA Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
finance.yahoo.com - November 30 at 3:43 PM
finance.yahoo.com logoAn Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 44% Undervalued
finance.yahoo.com - November 28 at 10:24 AM
businesswire.com logoNewly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor ...
businesswire.com - November 15 at 12:47 PM
finance.yahoo.com logoNewly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
finance.yahoo.com - November 15 at 12:47 PM
finance.yahoo.com logoChromaDex Corporation (NASDAQ:CDXC) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 10 at 4:40 PM
markets.businessinsider.com logoAnalysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE), Chromadex (CDXC) and Glaukos (GKOS)
markets.businessinsider.com - November 10 at 6:38 AM
finance.yahoo.com logoChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
finance.yahoo.com - November 9 at 12:39 PM
msn.com logoChromaDex GAAP EPS of -$0.01 beats by $0.02, revenue of $19.49M misses by $0.88M
msn.com - November 8 at 9:06 PM
benzinga.com logoChromaDex: Q3 Earnings Insights
benzinga.com - November 8 at 9:06 PM
finance.yahoo.com logoChromaDex Corporation Reports Third Quarter 2023 Financial Results
finance.yahoo.com - November 8 at 9:06 PM
finance.yahoo.com logoChromaDex Corp (CDXC) Reports Growth in Net Sales and Positive Adjusted EBITDA in Q3 2023
finance.yahoo.com - November 8 at 9:06 PM
benzinga.com logoEarnings Outlook For ChromaDex
benzinga.com - November 7 at 2:32 PM
businesswire.com logoChromaDex Debuts Clinical Strength Tru Niagen ® Pro 1,000mg Featuring Niagen ® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide ...
businesswire.com - November 1 at 3:53 PM
finance.yahoo.com logoChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide
finance.yahoo.com - November 1 at 9:55 AM
finance.yahoo.com logoChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
finance.yahoo.com - October 31 at 1:31 PM
finance.yahoo.com logoZesty Paws® & ChromaDex Crack the Code on Cellular Health for Dogs With 'Healthy Aging' Line
finance.yahoo.com - October 27 at 8:11 PM
finance.yahoo.com logoChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line
finance.yahoo.com - October 26 at 12:58 PM
finance.yahoo.com logoA Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients
finance.yahoo.com - October 2 at 1:50 PM
stocknews.com logoWhy Investors Are Flocking to These 3 Chemical Stocks?
stocknews.com - September 18 at 9:06 PM
finance.yahoo.com logoInsider Stock Buying Reaches US$1.3m On ChromaDex
finance.yahoo.com - September 3 at 6:11 PM
businesswire.com logoPreclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More ...
businesswire.com - August 24 at 3:31 PM
finance.yahoo.com logoPreclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN
finance.yahoo.com - August 24 at 9:58 AM
Get ChromaDex News Delivered to You Automatically

Sign up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

CDXC Media Mentions By Week

CDXC Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CDXC
News Sentiment

0.74

0.66

Average
Medical
News Sentiment

CDXC News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CDXC Articles
This Week

4

1

CDXC Articles
Average Week

Get ChromaDex News Delivered to You Automatically

Sign up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:CDXC) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners